Timing of Empagliflozin in Primary PCI: Pre-Reperfusion Versus Post-Reperfusion Versus Placebo in South Asian STEMI Patients

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 480 participants.

Also called NCT07749014

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 480 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07749014
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Pakistan (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07749014. Randomized; quadruple masking; primary purpose treatment. Start 2026-09-01 (anticipated); primary completion 2027-09-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Timing of Empagliflozin in Primary PCI: Pre-Reperfusion Versus Post-Reperfusion Versus Placebo in South Asian STEMI Patients
Acronym
TEMPO-STEMI
Condition
ST-elevation Myocardial Infarction (STEMI)
Condition
Acute Myocardial Infarction (AMI)
Intervention (Drug)
empagliflozin
Intervention (Drug)
Placebo
Lead sponsor
Rehman Medical Institute - RMI (class: other)
Collaborator
Michigan State University (class: other)

Record details

Record id
cardio:ct-nct07749014
Content hash
6852ff9ce7cb27256364ccea2e8c0ae9cc354332edb12ca27645c0e17db2feab